ALZHEIMER’S DISEASE RESEARCH
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.
If you are 55 to 90 years of age, you may be able to help if you:
· Are in good general health
· Have a diagnosis of early AD, Mild Cognitive Impairment (MCI) or are cognitively normal
· Are willing and able to undergo in-clinic assessments, memory testing and other test procedures
· Have a study partner who can accompany you to all clinic visits
· Are fluent in English or Spanish
This is a free study. No experimental medication will be involved.
To learn more, please visit http://www.adni3.org/
TRAILBLAZER-2: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.
Among others, criteria include:
– 60 Years to 85 Years of age
– Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
– Have a study partner who will provide written informed consent to participate
– No contraindication to MRI or PET scans
For more information, call Dr Traci Aladeen at 716-558-9918 or email firstname.lastname@example.org. You can also visit: https://clinicaltrials.gov/ct2/show/NCT04437511?term=donanemab&draw=2&rank=1
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects
Among others, criteria include:
– Age 55-90 years
– Have a reliable study partmer, an identified adult who has sufficient contact to knowledgeably report on the subject’s daily cognition, function, behavior, safety, compliance and adherence.
– Have a clinical diagnosis of mild-to-moderate AD
– Visual and auditory acuity adequate for neuropsychological testing
For more information, call Dr Traci Aladeen at 716-558-9918 or email email@example.com. You can also visit https://clinicaltrials.gov/ct2/show/NCT04251182?term=T3D-959&draw=2&rank=1
DIZZINESS AND BALANCE RESEARCH
Have you been diagnosed with Meniere’s disease? If so, you may be eligible for a clinical trial. This trial is being conducted to see if the Investigational Product helps with vertigo episodes in patients with Meniere’s disease.
To join the trial, you must meet these criteria*:
- Be from 18-85 years of age
- Have been diagnosed with Meniere’s disease in one ear
- Have had spinning (vertigo) episodes for 2 months before joining the trial
- Have no history of middle or inner ear surgery
* Other criteria will apply.
Qualified participants will receive at no cost:
- Investigational product of placebo (has no active ingredients) given by a one-time injection to the ear
- Trial-related exams and follow-up
- Education about condition
To learn more about this study, please contact Jennifer Cox at 716-250-7002.
Although our previous Tinnitus study has been closed, we anticipate more to come in the future. If you would like to be added to our list of those interested in future studies, please contact Jennifer Cox at 716-250-7002.
BRAIN TUMOR/ONCOLOGY RESEARCH
For information regarding brain tumor and oncology research contact Rebecca Hogan, Clinical Research Coordinator, at 716-558-5670
Focal Onset Epilepsy
X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension
A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.
To participate in the trial, you must meet certain criteria. The following details only some of these requirements.
Study participants must:
- Be between 18 to 75 years of age
- Have been diagnosed with focal epilepsy at least 2 years ago
- Be on treatment with stable dose of 1 to 3 AEDs
If you would like more information or to find out if you are eligible to participate please contact Jennifer Cox at 716-250-7002, or click here
We are looking for adults ages 18 to 55 who have been diagnosed with migraine. The CGBC Study will consist of five visits over a period of up to five weeks. Individuals will be evaluated to determine their eligibility to participate in this study. Each person who qualifies will receive the study drug and study-related medical exams at no cost, as well as compensation for time and travel.
If you would like more information or to find out if you are eligible to participate please contact Rebecca Hogan at 716-558-5670 or click here to learn more.
Chronic and Episodic Migraine Trials
The Headache Center has a wide variety of research trails for our patients to participate in. We run trials for preventative and acute treatment of migraine for patients suffering from chronic and episodic migraine. If you are interested in learning if you qualify for a research study, please call 716-558-5670 for more information.
Pediatric and Adolescent Migraine Treatment Trials
We are currently enrolling adolescent and pediatric migraine patients (ages 6-17) for both preventative and acute treatment of migraine. If you are interested in getting your child involved in a study, please call 716-558-5670 for more information
We are excited to be able to offer new treatment options for our cluster headache patients. To qualify for these trials you must be between 18-70 years of age and have a 1 year history of cluster headache diagnosis. If you are interested in participating please call 716-558-5670.
MULTIPLE SCLEROSIS RESEARCH
For information regarding Multiple Sclerosis research contact Dr. Michelle Rainka at 716-250-2038
PARKINSON’S DISEASE RESEARCH
Although our previous Parkinson’s Disease study has been closed, we anticipate more to come in the near future. If you would like to be added to our list of those interested in future studies, please contact Dr. Traci Aladeen at 716-558-9918 or firstname.lastname@example.org